Science & Technology Review
|
2023, 41(18): 43-51
• Exclusive:Cancer prevention and cure •
Antibody-drug conjugates in lung cancer: Current research status, challenges and prospects
Full
YANG Menghang, ZHOU Caicun*
Affiliations
Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
Published: 2023-09-28
doi: 10.3981/j.issn.1000-7857.2023.18.006
Outline
Antibody-drug conjugates (ADC) drugs have both the powerful killing effect of traditional chemotherapy drugs and the precise targeting of antibody drugs, bringing new hope for solving the dilemma of lung cancer treatment. This review article summarized the mechanism of action of antibody-drug conjugates (ADC), introduced the clinical research progress of ADC in lung cancer, analyzed the challenges of ADC application in lung cancer, and looked forward to the development direction and application prospects of ADC in lung cancer.
lung cancer
/
antibody-drug conjugates
/
precision therapy
YANG Menghang, ZHOU Caicun.
Antibody-drug conjugates in lung cancer: Current research status, challenges and prospects[J].
Science & Technology Review,
2023
, 41
(18)
: 43
-51
.
DOI: 10.3981/j.issn.1000-7857.2023.18.006
Year 2023 volume 41 Issue 18
PDF
972
536
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2023.18.006
- Receive Date:2023-07-28
- Online Date:2023-09-28
- Published:2023-09-28